FTC Puts No-Authorized-Generic Pharma Deals In Crosshairs
The Federal Trade Commission's first-of-its-kind enforcement action against Endo and other drugmakers lends the agency's formidable credibility to the theory that pharmaceutical companies can make anti-competitive payments by withholding authorized generics,...To view the full article, register now.
Already a subscriber? Click here to view full article